NDATOPICALAEROSOL, FOAM
Approved
May 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
OLUX (clobetasol propionate) by R-Pharm US is clinical pharmacology: the corticosteroids are a class of compounds comprising steroid hormones secreted by the adrenal cortex and their synthetic analogs. First approved in 2000.
Drug data last refreshed 11h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OLUX (clobetasol propionate 0.05%) is a super-potent topical corticosteroid formulated as an aerosol foam for dermatologic use. It works by suppressing inflammatory and immune responses in the skin through anti-inflammatory, antipruritic, and vasoconstrictive mechanisms. The drug is indicated for corticosteroid-responsive dermatoses, particularly scalp psoriasis and other inflammatory skin conditions.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30); brand team likely focused on line-extension, indication expansion, or managed decline.
Mechanism of Action
CLINICAL PHARMACOLOGY: The corticosteroids are a class of compounds comprising steroid hormones secreted by the adrenal cortex and their synthetic analogs. In pharmacologic doses, corticosteroids are used primarily for their anti-inflammatory and/or immunosuppressive effects. Topical…
Worked on OLUX at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.